[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369308-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369308-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-bioinformatics-analysis-of-tiprl-in-human-tumors-research-report","Pan-cancer bioinformatics analysis of TIPRL in human tumors - Research Report","","Pan-cancer bioinformatics study evaluates the TOR signaling pathway regulator-like (TIPRL) gene across multiple human cancers, focusing on expression patterns and clinical relevance. The analysis connects TIPRL with survival outcomes, genetic alterations, RNA modification signals, immune infiltration profiles, and tumor microenvironment markers. Methods integrate TCGA-GTEx and CPTAC datasets in R and multiple bioinformatics platforms, complemented by cBioPortal, STRING, ssGSEA, and pathway enrichment to clarify potential prognostic and therapeutic value.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-bioinformatics-analysis-of-tiprl-in-human-tumors-research-report/369308/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-bioinformatics-analysis-of-tiprl-in-human-tumors-research-report/369308.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study evaluate about TIPRL across cancers?","Question",{"text":63,"@type":64},"It assesses TIPRL expression patterns across multiple tumor types and examines associations with survival, genetic alterations, RNA modifications, immune infiltration, and functional pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which data sources and tools are used for the analysis?",{"text":68,"@type":64},"The study uses TCGA-GTEx and CPTAC data analyzed in R, with GEPIA2 and UALCAN for expression/prognostic context, cBioPortal for genetic alterations and 3D structures, and STRING plus R-based enrichment and ssGSEA for pathway and immune analyses.",{"name":70,"@type":61,"acceptedAnswer":71},"What key findings connect TIPRL to tumor progression and immunity?",{"text":72,"@type":64},"TIPRL is elevated in most cancers, correlates with worse overall survival in several types, shows links to genetic amplifications and RNA modifications (including m1A, m5C, m6A), and displays variable correlations with immune cell infiltration, immune scores, and genomic instability markers such as TMB, MSI, and HRD.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369308,1790244888,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Analysis  \nPan‑cancer bioinformatics analysis of TIPRL in human tumors  \nXuezhong Zhang1 · Hao Xue2 · Yuanyuan Lv3 · Yuntao Zhou1 · Kaihui Sha4 · Tonggang Liu5  \nReceived: 15 November 2024 / Accepted: 5 March 2025  \n© The Author(s) 2025 OPEN  \nAbstract  \nIntroduction The TOR signaling pathway regulator-like (TIPRL) gene plays a multifaceted role in cancer, yet its pan-cancer profile remains underexplored. This study investigates TIPRL expression across multiple cancers and its associations with survival, genetic alterations, immune infiltration, and functional pathways, providing insights into TIPRL’s role as a potential prognostic and therapeutic target.  \nMethods TIPRL expression and prognostic significance across tumor types were analyzed using TCGA_GTEx and CPTAC data in R software and platforms like GEPIA2 and UALCAN. Genetic alterations and 3D structures were evaluated through cBioPortal. Associations with RNA modifications, immune checkpoints, immune cell infiltration, TMB, MSI, HRD, and enriched pathways were assessed via R and STRING databases, employing survival analysis, ssGSEA, and enrichment analyses.  \nResults TIPRL expression was elevated in most cancers, with significant stage-specific associations observed in KICH, KIRP, and LUSC. High TIPRL expression correlated with worse overall survival in ACC, BRCA, HNSC, KICH, LIHC, and MESO, suggesting its role in prognosis. Genetic analysis identified amplifications as the main alteration, with varied clinical relevance across cancers. RNA modifications in TIPRL, particularly m1A, m5C, and m6A, suggested potential regulatory mechanisms. Immune infiltration analysis revealed TIPRL’s varied correlations with immune cell types and immune scores, differing by cancer type. TIPRL also positively correlated with TMB, MSI, and HRD in several cancers, indicating its association with genomic instability. Enrichment analyses highlighted TIPRL’s involvement in processes like oxidative phosphorylation and autophagy, underscoring its influence in tumorigenesis.  \nConclusion These findings establish TIPRL as a significant biomarker in cancer progression and immune regulation, warranting further exploration into its therapeutic implications across diverse tumor types.  \nKeywords TOR signaling pathway regulator-like (TIPRL) gene · Pan-cancer · Tumor · Bioinformatics analysis  \nAbbreviations:  \nACC Adrenocortical carcinoma BLCA Bladder Urothelial Carcinoma  \nXuezhong Zhang, Hao Xue and Yuanyuan Lv are share first authorship.  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-025-](https://doi.org/10.1007/s12672-025-)[ ](https://doi.org/10.1007/s12672-025-)[02070-9](02070-9.)[.](02070-9.)  \n* Yuntao Zhou, [18678187219@163.com](18678187219@163.com); * Kaihui Sha, [Skhui328175@163.com](Skhui328175@163.com); * Tonggang Liu, [Liutonggang123@126.com |](Liutonggang123@126.com |)  \n[1](1Department of Laboratory Medicine)[Department of Laboratory Medicine](1Department of Laboratory Medicine), [Zibo Central Hospital](Zibo Central Hospital), [Zibo](Zibo), [Shandong](Shandong), [China](China). 2Department of Neurology, Zibo Central Hospital,  \nZibo, Shandong, China. 3Department of Cardiology, Zibo Central Hospital, Zibo, Shandong, China. 4Binzhou Medical University School of Nursing, Binzhou, Shandong, China. 5Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou, Shandong, China.  \nDiscover Oncology  \n(2025) 16:320  \n| [https://doi.org/10.1007/s12672-025-02070-9](https://doi.org/10.1007/s12672-025-02070-9)  \nBRCA Breast invasive carcinoma  \nCESC Cervical squamous cell carcinoma and endocervical adenocarcinoma CHOL Cholangiocarcinoma  \nCOAD Colon adenocarcinoma  \nDLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma ESCA Esophageal carcinoma  \nGBM Glioblastoma multiforme  \nHNSC Head and Neck squamous cell carcinoma KICH Kidney Chromophobe  \nKIRC Kidney renal clear cell carcinoma KIRP Kidney renal papil","cbCaifkL6Pgcv3hW","https://ap.wps.com/l/cbCaifkL6Pgcv3hW","pdf",13428376,17,"English","# Introduction\n## Methods\n## Results\n## Conclusion\n## Abbreviations","[{\"question\":\"What does the study evaluate about TIPRL across cancers?\",\"answer\":\"It assesses TIPRL expression patterns across multiple tumor types and examines associations with survival, genetic alterations, RNA modifications, immune infiltration, and functional pathways.\"},{\"question\":\"Which data sources and tools are used for the analysis?\",\"answer\":\"The study uses TCGA-GTEx and CPTAC data analyzed in R, with GEPIA2 and UALCAN for expression/prognostic context, cBioPortal for genetic alterations and 3D structures, and STRING plus R-based enrichment and ssGSEA for pathway and immune analyses.\"},{\"question\":\"What key findings connect TIPRL to tumor progression and immunity?\",\"answer\":\"TIPRL is elevated in most cancers, correlates with worse overall survival in several types, shows links to genetic amplifications and RNA modifications (including m1A, m5C, m6A), and displays variable correlations with immune cell infiltration, immune scores, and genomic instability markers such as TMB, MSI, and HRD.\"}]","Pan-cancer bioinformatics analysis of TIPRL in human tumors - Research Report | PDF",1790181872,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32438c1e280c86f8492b3e26b7f686ad.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e6e5348ce16170fa88c212e5b4e28f8.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45e146e6642cb103006329bd5832155f.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c021ae346391eaed8e2a9c61ea19103d.webp",980,1301]